Page 14 - <>期刊 v2

14
Back
ID D N U | iddnu@suntrap.com | www.suntrap.com

mL; (2) LeSoleil-T showed a 99.41% inhibition on In addition, SARS-CoV-2 viruses can easily bind to sial-
SARS-CoV-2 virus at a concentration of 121.06 μg/ ic acid to avoid being detected by the human immune
mL; and (3) a high inhibitory effect on SARS-CoV-2 (> system.
63.06%) can be achieved at ultra-low concentrations
A series of cascade reactions in lung can be triggered
(0.195~1.562 μg/mL). In the stage of demonstrating
by a variety of cytokines and chemotactic factors
the relationship between toxicity, dosage, and biolog-
after the large number of SARS-CoV-2 replication in
ical efficacy, the experimental results of the rat model
the oral and nasal cavity and its entering into lung
showed that the LD of LeSoleil-T is greater than 5
50 through the pharyngeal respiratory tract, which re-
g/kg, indicating that LeSoleil-T has high safety at the
sults in severe lung inflammation and pathology.
animal level.
The virus causes damage to lung tissue, where lung
To clarify the pharmacological function of LeSoleil-T atrophy and pulmonary edema can occur, affecting
against COVID-19, the Suntrap research team con- the body’s exchange of oxygen and resulting in acute
ducted systematic analysis of the infection mecha- respiratory distress, which contribute to the leading
nisms of SARS-CoV-2. Previous studies have shown cause of death for many severely infected patients.
that SARS-CoV-2 virus infects human cells through After entering the lung, SARS-CoV-2 spreads rapidly
two major routes: endocytic and non-endocytic in the human body, resulting in systemic infection and
routes. Commonality is presented in these two infec- illnesses, including viral infection, lung inflammation,
tious processes. Both of them activate the spike pro- gastrointestinal dysfunction, and damages to the cen-
tein of SARS-CoV-2 through the TMPRSS2 protease of tral nervous system, peripheral nervous system, myo-
the host cell. Subsequently, the spike protein binds to cardial fibers and myocardial cells, liver and kidney
ACE2 receptor protein on the surface of the host cell, tissues, as well as muscle tissues.
to allow the virus or its nucleic acid to enter the host
In view of the inhibitory effects of LeSoleil-T against
cell, and the SARS-CoV-2 is finally replicated with the
SARS-CoV-2, the pharmacological mechanisms of
help of the M protein.
pro
LeSoleil-T were explored through a series of experi-
SARS-CoV-2 viruses enter the oral and nasal cavity mental assays. The results showed that LeSoleil-T has
through the respiratory tract. The mucosa of the na- pharmacological effects in the treatment of SARS-
sal/oral cavity provides surfaces for the direct contact CoV-2 infection as the following: broad-spectrum
area with air. In addition, the ACE2 receptor protein anti-coronavirus inhibitory effects, anti-inflammatory
is highly expressed on nasal mucosal cells. Therefore, effects, neuron protections, delay and reversal of tis-
the oral pharynx and nasal cavity are easily infected sue fibrosis.
by SARS-CoV-2 virus. The viruses will enter the sinus-
Based on the above results, the Suntrap team has
es through the nasal cavity after infecting the cells in
obtained the Chinese invention patent authorization
the nasal cavity. There are four cavities around the
for the broad-spectrum anti-coronavirus in January
sinuses: frontal sinus, sphenoid sinus, ethmoid sinus
2021, and has filed international patent applications
and maxillary sinus. All of the sinuses are connected
through the PCT, and applied for patent protection in
to the nasal cavity. SARS-CoV-2 can hide in these four
many countries and regions.
cavities and will be released after massive replication.